The main benefit of xenotransplantation is its potential to overcome the worldwide organ shortage experienced in allotransplantation.
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2/21 physiological needs in large animal models; iii) the source of pig cells can be scaled-up to meet demands in a highly standardised manner, and with respect to animal welfare regulations; iv) designatedpathogen-free (DPF) pig lines can be produced, which could result in a higher safety profile than allotransplantation itself; v) the risk of zoonosis, which was raised years ago as the major hurdle, has been recently circumvented and is actually viewed as a controlled risk; and vi) immune risks are being circumvented via the use of genetically modified donor animals and encapsulation of porcine cells, particularly for the treatment of diabetes. Overall, the benefit appears to outweigh potential risks with respect to cellular xenotransplantation and this is discussed further in this review.
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Background
Transplantation represents the ideal treatment option for many patients in terminal organ failure. Indeed, it has been clearly demonstrated that transplantation is associated with improved quality of life, extended patient survival, and reduced costs to society. However, transplantation is severely limited by a tremendous organ shortage and, as a consequence, benefits only a minority of patients. Most patients must continue with ongoing, expensive treatment. For instance, worldwide, over two million people affected by chronic kidney disease currently receive treatment with dialysis (instead of a transplant) to stay alive, with an overall cost of around 80 billion euros per year. Likewise, it is estimated that the total worldwide number of type 1 diabetic patients regularly injecting insulin is between 10 and 20 million (1).
In light of this, it is of the utmost importance to identify novel sources of organs, tissues or cells to satisfy the clinical need. In this context, xenotransplantation, or transplantation of organs, cells or tissues between individuals belonging to two different species, such as from animals into humans, represents a potential solution to meet this (2, 3, 4) . Indeed, ethical considerations are an integral part of any xenotransplantation practice, and experts in ethics have been, and still are, involved in these important issues and are contributing to the development and harmonisation of guideline policies (5). This, however, is not the purpose of this paper and will not be discussed further.
Assessing benefits and risks
The risk of infection Each innovative medicinal product carries its own risks when administered to a patient, and a xenotransplantation product is no exception. The first risk factor that attracted attention was the potential transmission of infectious agents to the recipient, with resulting disease. This is relevant in view of the fact that a xenotransplantation product comprises living xenogeneic cells/tissues/organs, which precludes the sterilisation procedure that is possible for drugs and biologicals. The microbial risk of xenotransplantation is similar to that of autologous and allogenic cell therapy products; however, due to the nature of the source material, provided more details. These regulatory documents address products from any species transplanted to humans, but in the following discussion, the donor will be limited to the swine species because this is currently the generally accepted species for a xenotransplantation product.
The microbial risks of a xenotransplantation product can roughly be divided into three main categories (7):
-transmission of infectious agents that are pathogenic for humans but may not be pathogenic or even detectable in the source animal host -transmission of organisms that may not normally be pathogenic in humans but can become so in the immunosuppressed or immunocompromised individual -recombination or re-assortment of infectious agents, particularly viruses, with non-pathogenic or endogenous human infectious agents, to form new pathogenic entities.
These categories, however, do not mention infectious agents that are pathogenic for swine and can cause swine disease.
Concerns about the microbial safety risk of using pigs in xenotransplantion were raised when there were reports of pig-tohuman transmission of porcine endogenous retrovirus (PERV) (it should be emphasised that clinical trials at that time were not discontinued, but only put on hold awaiting the development and implementation of monitoring protocols) (9). Subsequently, the initial concerns about the human tropism of PERV developed into a more general concern about a wider range of pathogens, including exogenous infectious agents, in particular, porcine viruses. This concern about transmission of infectious agents from donor to human recipients has resulted in the use of a new designation, namely 'designated-pathogen-free' (DPF). (It is important to note that DPF does not mean that animals are gnotobiotic, i.e. devoid of any infectious pathogen in all body compartments, including the alimentary tract; such a status is even more complicated to achieve in sustained production than the DPF status. Also, endogenous pathogens such as PERV are not included in the DPF status simply because of their endogenous presence.)
Like the designation 'specific-pathogen-free' (SPF), which is widely used in biomedicine, DPF designation is not associated with a single prescribed list of pathogens that should not be present in the donor animals. Instead, pathogen exclusion lists, which should be presented and agreed with regulatory agencies, are proposed by the regulator, scientific community (10) and also by institutions preparing for clinical trials (11, 12) . These lists may differ between continents and between countries, depending on the infectious agents that are present.
There may also be different lists required for different xenotransplantation products, depending on the organ and tissue distribution of infectious agents and the processing of the organs or tissues before being administered to patients (13) .
Achieving the biosecurity barrier needed to achieve DPF status requires special conditions of breeding and husbandry (7, 14, 15) . The most relevant factors to consider in maintaining a barrier to disease and preserving the health status of the animals are the building, the location, feed, staff, and the number of animals. The number of animals within the biosecure barrier should not only be sufficient for production of donors in, for example, clinical trials, but also be sufficient to avoid inbreeding in outbred animal herds. In general, the operations in the animal facility should be in compliance with the Good Manufacturing Practices employed in similar fields. Also, accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (www.aaalac.org) is recommended.
From a risk perspective, there should be a programme for regular monitoring of the infectious agents on the agreed list of pathogens to be excluded. The frequency of sampling (blood, secretions or faeces) from the donor animals or of detailed investigation of sentinel animals, depends on the health status of the herd after its initial the cost risks. The following points are worth noting when considering whether or not such a barrier is necessary:
-Caesarian sectioning and colostrum deprivation of the first population in an SPF-like facility may be sufficient (14). In other words, the building and operations are under less strict conditions than they would be if DPF status were required. An example is the facility for minipigs run by Ellegaard-Göttingen in Denmark (16, 17) .
-A proper selection of founder animals in facilities with high hygiene standards could serve the same purpose. A requirement for such facilities is that they be siutated in remote locations so as to avoid potential entry of pathogens from the environment.
-Barriers other than physical barriers could serve to establish a DPF
status. An example is the placenta, in the case that newborn piglets are used as the donor. In this case, the sows should be monitored during pregnancy for pathogens and virus activation, which can result in transmission through the placenta.
-To assist with the costs associated with barrier facilities, some xenotransplantation products could be subject to a restricted pathogen exclusion list if, for example, distinct cells or tissues lack infection with specific viruses of concern. Cell products that are encapsulated before implantation could also be subject to a restricted list, as discussed in the recently published update of the consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes (8, 18).
-The processing of tissue and organs and the time period of processing should also be considered. This particularly applies to some cell therapy products that require a long period of culture after cell isolation or establishment of cell lines before the product is released for administration. In this situation the microbial presence in the pig is quite remote from the final product (11, 13) .
It thus appears that a high-hygiene biosecure barrier might not be necessary in all cases of a xenotransplantation product. Hence, instead (20), but the basic question of whether or not a xenotransplantaion product poses an infectious risk has not been answered definitively. At the moment, the assessment of microbial safety is mostly limited to animal models used for the purposes of testing the efficacy of xenotransplantation products, which are not always suitable.
It is quite understandable that, considering the many unknowns regarding potential infection of a recipient of a xenotransplantation product by the product itself, regulatory agencies, in a risk-aversive approach, require donor animals to be devoid of any infectious pathogen. But studies, as well as many trials with/without regulatory oversight on living porcine products administered to humans, have, to date, not shown indications for pig-to-human pathogen transmission.
Essentially, all the studies conducted to date suggest that a porcine xenotransplantation product is well tolerated and fairly safe, including from a microbial standpoint (12, 21, 22, 23) . It has also been noted in the literature that the risk from PERV may no longer be as significant as initially perceived (24, 25, 26) .
Thus, it is tempting to conclude that, with the suggested strategies in place, xenotransplantation products will have a much better pathogen safety profile than the allogeneic living organs, tissue and cell preparations that are currently used in clinical practice. Selection of donors meeting high-quality health standards, and implementation of rigorous quality control to monitor organ and ischemia damage during procurement, transport and processing, are of high importance. So, at SCOBIE_forPB33 9/21 least in theory, the ultimate risk-benefit ratio of a xenotransplantation product is expected to be much higher than that of a human-derived allogeneic product.
At this point, it is worth providing further explanation of the word is also a reality in the clinic today, and neural cell transplantation is in the early development stage (28, 29, 30) . However, and regardless of tissue-specific considerations and difficulties, a common major obstacle standing in the way of widespread use of cell transplantation SCOBIE_forPB33 10/21
is the lack of human donors, and this has led to the search for alternative sources of cells from other species. In this context, pigs have emerged as suitable candidates for providing xenocells due to anatomical and physiological similarities with humans. In the case of treatment for type I diabetes, porcine islets could meet the demand and have several advantages, including the functionality of porcine insulin in humans due to high similarity in protein sequence, which supports the case for using pigs as a donor species (reviewed in [31, 32] ).
Moreover, it is possible to genetically modify donor pigs to mitigate the host immune reaction to xenografted cells and to adapt their function to human physiology when needed, which will definitely accelerate the transition of cell xenotransplantation from the bench to the clinic. The first exploratory health economic evaluation of a porcine islet xenogenic cell therapy product showed that this product may prove to be a cost-effective and possibly cost-saving procedure for type 1 diabetes compared to standard management using insulin treatment, even thought the costs per pig are quite high (33) .
Regarding methods of delivering islets into the recipient, the methods currently preferred are: intra-portal transplantation, as performed in allotransplantation, for free porcine islets (wild-type or genetically modified); extra-peritoneal implantation for macroencapsulated islets; intraperitoneal implantation for microencapsulated islets; and subcutaneous implantation for macroencapsulation devices.
Intramuscular implantation of free islets is also currently under investigation (28, 34, 35, 36) . However, the free transplantation of such non-encapsulated cell sources, in humans, is not yet permitted by the EMA due to possible transfer of pathogens and because of the risk of uncontrolled cell replication in the recipient organism, although a recent study demonstrated a lack of pathogen transmission to marmosets (23) .
Another limitation of cell transplantation is the need for immunosuppression. Allo-or xeno-transplantation of insulin-secreting cells in humans is possible, but it elicits a severe immune rejection requiring immunosuppressive treatment of the recipient. This treatment, although beneficial in preventing islet rejection, has Permselective membranes protect the transplanted cells against the recipient's immune system, but allow oxygen and nutrient supply (reviewed in [37] ). There are still major immunological obstacles to successful clinical islet xenotransplantation, but strategies to overcome these have been developed. Some genetic modifications, e.g. elimination of proinflammatory molecules or insertion of transgenes to improve survival and function, may also be beneficial for encapsulated islets (31) . Alternatively, human beta-cells can be produced from pluripotent stem cells. Their delivery route strategy is similar to that described above, as avoidance of immune rejection of allogenic donor cells follows the same logic. In theory, use of patient-derived induced pluripotent stem cells (iPSCs) would allow for autologous beta-cell production and transplantation. However, this is considered an economically non-viable option at the moment due to the current technological limitations.
A number of clinical xenotransplantation trials in humans have already been described in the literature and deemed safe (12, 13, 22) . Efficacy confirmation requires further research; however, in the context of islet cells, the risk is considered low.
Risks posed by genetic modification
Cutting edge research is dependent on genetic engineering/genome editing for the purpose of creating suitable surrogates for the study of genetic diseases (38, 39, 40, 41) and regenerative medicine (42), or for supplying an unlimited source of cells, tissues, organs and scaffolds that can be used effectively and safely for transplantation to cure human diseases (43) . Multi-transgenic pigs have already been generated by classical means of homologous recombination and/or random integration. The development of GGTA1-KO pigs was a fundamental step in reducing the risk of immune rejection in SCOBIE_forPB33 12/21 xenotransplantation. Now, multiple transgenes can be introduced on a donor genetic background, not only to mitigate immune complications but also to improve the function and production of insulin (44) . With the use of programmable nucleases, multiple recombination events (ins/del or homology directed repair) can be obtained in one single step. Targeted integration can ensure the optimal performance of any transgene integrated, therefore increasing the efficacy of the expected function.
To date, the multi-transgenic pigs generated by conventional means for xenotransplantation are healthy and can reproduce. However, unexpected phenotypes can develop after repeated rounds of multiple genetic engineering, vital function can be affected, and side effects due to inadequate transgene function can occur. With genome editing, the same concerns may arise, but the precise genetic modification that can be obtained should be of less concern. Genome editing technology has significantly evolved since the initial reports (43) . Accordingly, recent work has demonstrated remarkable survival rates. For example, in baboons, the use of transgenic pigs for heterotopic cardiac xenografts, coupled with an aggressive immunosuppression regimen, resulted in post-transplantation survival rates of up to almost three years (45) .
Progress in the field of xenotransplantation has changed gear since nuclease-based techniques have been implemented for editing the pig genome (46, 47, 48, 49) . The number of transgenic animals with inactivated genes and/or integrated novel transgenes has dramatically increased, thus facilitating the development and completion of preclinical studies (40, 41, 42, 50, 51, 52, 53, 54) . Genome editing in live pigs is required to test the safety and efficacy of this technology for xenotransplantation products. Although potential off-target effects are often indicated as possible complications, animals generated after genome editing do not appear to be different from those generated by conventional technologies. Therefore, there are no fundamental reasons why genetically modified pigs utilising gene editing pose a priori different risks compared with those engineered by conventional SCOBIE_forPB33 13/21 transgenesis. However, risks should be carefully assessed case by case depending on the modified/added genes.
Finally, PERV has been the main focus of concern in gene editing due to their presence as integrated elements in the pig genome, but recent work using CRISPR/Cas9 technology has convincingly demonstrated that multiple copies of PERV can be targeted simultaneously to obtain PERV-free cells (55) . However, it is yet to be demonstrated that this technology can give rise to healthy animals.
Conclusion
It is clear that the use of xenotransplantation to treat human disease would be of great benefit but can pose a risk. However, it is also clear that many of these risks can be overcome with careful consideration and planning. The future of clinical xenotransplantation is particularly bright with respect to the use of porcine cells and their use should be supported as an alternative to current methods. 
